ORICHealthcare · BiotechnologyThe 14 Wall Street analysts covering Oric Pharmaceuticals, Inc. hold a median 12-month price target of $22 — +67.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 5 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Oric Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (75): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ORIC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +67.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $25 → $27 |
| 8 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 15 May 2026 | Goldman Sachs | Upgrade | Buy | — |
| 5 May 2026 | Citigroup | Maintains | Buy | — |
| 2 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 13 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Feb 2026 | Citigroup | Maintains | Buy | — |
| 24 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Feb 2026 | Wedbush | Reiterates | Outperform | — |
| 13 Jan 2026 | Wedbush | Reiterates | Outperform | — |
| 7 Jan 2026 | Piper Sandler | Initiates | Overweight | — |
| 8 Dec 2025 | Wedbush | Reiterates | Outperform | — |
| 8 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 20 Nov 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 18 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 18 Nov 2025 | Wolfe Research | Initiates | Peer Perform | — |
| 17 Nov 2025 | Citigroup | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ORIC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Sept 2026, Oric Pharmaceuticals, Inc. returned +19.4% against +20.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 30% of US stocks
Cheaper than 81% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 24% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Oric Pharmaceuticals, Inc. has a market value of $1.3B and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$140.4M.
Diluted earnings per share, trailing twelve months: $−1.35.
Free cash flow in the twelve months to 30 June 2026: −$112.3M.
Trailing P/E: −8.7×; forward P/E: −8.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Oric Pharmaceuticals, Inc. employs 111 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Oric Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ORIC Pharmaceuticals announced inducement grants under Nasdaq Listing Rule 5635(c)(4) from its South San Francisco and San Diego offices. The company reported the grants in a news release from GlobeNewsWire.
Why it matters — ORIC watchers may want to track the inducement grants as they reflect how the company is incentivizing new talent under Nasdaq rules.
ORIC Pharmaceuticals announced that its management will participate in several investor conferences in September. The company is a clinical-stage oncology firm focused on treatments addressing mechanisms of therapeutic resistance.
Why it matters — ORIC watchers would care because management participation at investor conferences provides opportunities for the company to present its clinical-stage oncology pipeline and engage with the investment community.
ORIC Pharmaceuticals announced that on August 3, 2026, it granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees who joined the company in July 2026. The grants were made under Nasdaq Listing Rule 5635(c)(4) as inducement awards.
Why it matters — This disclosure reflects ORIC's equity-based incentive awards to newly hired personnel, which is relevant to investors tracking the company's compensation and share-dilution practices.
ORIC Pharmaceuticals reported second quarter 2026 financial results and operational updates, including initiation of the Himalayas-1 global Phase 3 trial in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone, and a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for that trial. The company expects to provide a rinzimetostat program update and enozertinib clinical updates in the second half of 2026 ahead of a potential registrational trial, and its roughly $388 million in cash and investments is expected to fund operations into the second half of 2028.
Why it matters — ORIC watchers would care because the quarter brought a new global Phase 3 trial and a Bayer collaboration, along with near-term program updates that could shape the company's registrational path.
The 14 Wall Street analysts covering Oric Pharmaceuticals, Inc. have a median 12-month price target of $22, with estimates ranging from $14 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Oric Pharmaceuticals, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oric Pharmaceuticals, Inc. 49 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Sept 2026, Oric Pharmaceuticals, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (75 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +67.2% from the last close, and Ticker Nerd's factor model ranks Oric Pharmaceuticals, Inc. 49 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Oric Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORIC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $27 over the next 12 months.
Oric Pharmaceuticals, Inc. returned +19.4% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment.
The most recent item we track (GlobeNewsWire, 4 Sept 2026): "ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)". ORIC Pharmaceuticals announced inducement grants under Nasdaq Listing Rule 5635(c)(4) from its South San Francisco and San Diego offices. The company reported the grants in a news release from GlobeNewsWire.
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that address resistance to treatment. The company’s research pipeline centers on precision oncology, hormone-dependent cancers, and key tumor dependencies, with current programs designed to target mechanisms that limit the effectiveness of existing cancer medicines. Its product candidates include therapies in clinical development for genetically defined cancers and prostate cancer, along with additional discovery-stage oncology programs. Oric Pharmaceuticals operates as a single business segment and concentrates its efforts on advancing research, clinical development, and translational science for cancer treatment. The company is headquartered in South San Francisco, California, with additional operations supporting its development work in the United States. Its role in the market is to contribute experimental oncology candidates to the broader pipeline of targeted cancer therapeutics.
CEO Dr. Jacob M. Chacko M.B.A., M.D. · 111 employees · United States · https://www.oricpharma.com
